Insider Trading Alert - NMRX, AMNB And VRX Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 27, 2015, 82 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $945.00 to $3,999,999.00.

Highlighted Stocks Traded by Insiders:

Numerex (NMRX) - FREE Research Report

Nicolaines Stratton J, who is CEO, Chairman of the Board at Numerex, bought 5,000 shares at $8.62 on May 27, 2015. Following this transaction, the CEO, Chairman of the Board owned 117,336 shares meaning that the stake was boosted by 4.45% with the 5,000-share transaction.

Ryan Andrew J, who is Secretary & General Counsel at Numerex, bought 2,000 shares at $8.50 on May 27, 2015. Following this transaction, the Secretary & General Counsel owned 205,120 shares meaning that the stake was boosted by 0.98% with the 2,000-share transaction.

The shares most recently traded at $8.60, up $0.10, or 1.15% since the insider transaction. Historical insider transactions for Numerex go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 20,000
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 20,000
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 20,000

The average volume for Numerex has been 47,300 shares per day over the past 30 days. Numerex has a market cap of $163.8 million and is part of the technology sector and telecommunications industry. Shares are down 21.97% year-to-date as of the close of trading on Wednesday.

Numerex Corp., through its subsidiaries, provides interactive and on-demand machine-to-machine (M2M) enterprise solutions for the enterprise and government markets worldwide. The company has a P/E ratio of 287.7. Currently, there are no analysts who rate Numerex a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NMRX - FREE

TheStreet Quant Ratings rates Numerex as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity. Get the full Numerex Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

American National Bankshares (AMNB) - FREE Research Report

Pleasant Dan Miller, who is Director at American National Bankshares, bought 458 shares at $22.30 on May 27, 2015. Following this transaction, the Director owned 5,465 shares meaning that the stake was boosted by 9.15% with the 458-share transaction.

The shares most recently traded at $22.77, up $0.47, or 2.06% since the insider transaction. Historical insider transactions for American National Bankshares go as follows:

  • 4-Week # shares bought: 50
  • 4-Week # shares sold: 5,000
  • 12-Week # shares bought: 50
  • 12-Week # shares sold: 5,000
  • 24-Week # shares bought: 50
  • 24-Week # shares sold: 5,000

The average volume for American National Bankshares has been 11,000 shares per day over the past 30 days. American National Bankshares has a market cap of $196.7 million and is part of the financial sector and banking industry. Shares are down 8.18% year-to-date as of the close of trading on Wednesday.

American National Bankshares Inc. operates as the bank holding company for American National Bank and Trust Company that provides financial products and services to individuals and businesses in Virginia and North Carolina. The stock currently has a dividend yield of 4.08%. The company has a P/E ratio of 14.3. Currently, there are no analysts who rate American National Bankshares a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMNB - FREE

TheStreet Quant Ratings rates American National Bankshares as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, expanding profit margins and attractive valuation levels. We feel its strengths outweigh the fact that the company has had somewhat weak growth in earnings per share. Get the full American National Bankshares Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Valeant Pharmaceuticals International (VRX) - FREE Research Report

Whitaker Anne Clem, who is Director at Valeant Pharmaceuticals International, bought 7,500 shares at $234.67 on May 27, 2015. Following this transaction, the Director owned 7,500 shares meaning that the stake was boosted by 100% with the 7,500-share transaction.

The shares most recently traded at $240.33, up $5.66, or 2.36% since the insider transaction. Historical insider transactions for Valeant Pharmaceuticals International go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 10,000
  • 24-Week # shares bought: 500
  • 24-Week # shares sold: 10,000

The average volume for Valeant Pharmaceuticals International has been 2.2 million shares per day over the past 30 days. Valeant Pharmaceuticals International has a market cap of $80.6 billion and is part of the health care sector and drugs industry. Shares are up 67.09% year-to-date as of the close of trading on Wednesday.

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company has a P/E ratio of 79.8. Currently, there are 8 analysts who rate Valeant Pharmaceuticals International a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRX - FREE

TheStreet Quant Ratings rates Valeant Pharmaceuticals International as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Valeant Pharmaceuticals International Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Component Stocks Rise After Trump Reverses Decision on ZTE

Component Stocks Rise After Trump Reverses Decision on ZTE